AANS Neurosurgeon | Volume 29, Number 2, 2020


Smart Bomb Virus Shows Promise as Brain Tumor Immunotherapy

Print Friendly, PDF & Email

In clinical trial, 20 percent of patients with recurrent glioblastoma live 3-plus years


A common cold virus engineered to attack the most common and deadly of brain tumors allowed 20 percent of patients with recurrent glioblastoma to live for three years or longer, researchers from The University of Texas MD Anderson Cancer Center report on a phase I clinical trial.

The altered adenovirus, called Delta-24-RGD or DNX-2401, was injected one time directly into the tumors of 25 patients whose glioblastoma had recurred after surgery and other treatments, a patient group that typically has a median survival of six months.

“Of those five long-term survivors, three had durable complete responses, which is impressive for a phase I clinical trial in glioblastoma,” said lead author Frederick Lang, M.D., professor of Neurosurgery.  “Many phase I trials might have one patient who does well, so our result is unusual, but we’re always cautious in assessing results with this very difficult disease.”

Click here to read more.


No upcoming events

Comments are closed.